Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

ANDREW N DAUBER

Allopathic & Osteopathic Physicians Pediatrics Pediatric Endocrinology

NPI
1457410813
CMS profile
338628
Location
CINCINNATI, OH

General Payments · PY2018–2024

$143,912.15

  • Reported across 88 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$54,459.31

28 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
BioMarin Pharmaceutical Inc. $38,960.96 18
Novo Nordisk Health Care AG $13,424.28 8
Neurocrine BioSciences, Inc. $2,074.07 2

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $4,262.41 4
PY2019 $22,429.07 16
PY2020 $2,090.00 3
PY2021 $15,980.00 12
PY2022 $30,779.95 13
PY2023 $13,911.41 12
PY2024 $54,459.31 28

Payment records · PY2024 (28)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
BioMarin Pharmaceutical Inc. $21.32 03/13/2024 Food and Beverage Undisputed 01/23/2026 1127058561 CMS
BioMarin Pharmaceutical Inc. $36.58 09/21/2024 Food and Beverage Undisputed 01/23/2026 1127061892 CMS
BioMarin Pharmaceutical Inc. $272.49 10/15/2024 Food and Beverage Undisputed 01/23/2026 1127058131 CMS
BioMarin Pharmaceutical Inc. $842.01 10/15/2024 Travel and Lodging Undisputed 01/23/2026 1127058151 CMS
BioMarin Pharmaceutical Inc. $14,608.54 10/15/2024 Travel and Lodging Undisputed 01/23/2026 1127058171 CMS
BioMarin Pharmaceutical Inc. $341.91 11/07/2024 Travel and Lodging Undisputed 01/23/2026 1127058465 CMS
BioMarin Pharmaceutical Inc. $209.00 11/07/2024 Travel and Lodging Undisputed 01/23/2026 1127058987 CMS
BioMarin Pharmaceutical Inc. $205.71 11/07/2024 Food and Beverage Undisputed 01/23/2026 1127059017 CMS
BioMarin Pharmaceutical Inc. $34.19 11/07/2024 Travel and Lodging Undisputed 01/23/2026 1127059091 CMS
BioMarin Pharmaceutical Inc. $44.00 11/16/2024 Food and Beverage Undisputed 01/23/2026 1127062096 CMS
BioMarin Pharmaceutical Inc. $43.67 11/17/2024 Food and Beverage Undisputed 01/23/2026 1127062108 CMS
BioMarin Pharmaceutical Inc. $6,000.00 12/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1127063036 CMS
BioMarin Pharmaceutical Inc. $2,400.00 12/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1127063092 CMS
BioMarin Pharmaceutical Inc. $2,500.00 12/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1127059125 CMS
BioMarin Pharmaceutical Inc. $2,500.00 12/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1127063072 CMS
BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 1127057877 CMS
BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 1127057879 CMS
BioMarin Pharmaceutical Inc. $2,967.18 12/31/2024 Consulting Fee Undisputed 01/23/2026 1127057881 CMS
Neurocrine Biosciences, Inc. $74.07 05/03/2024 Food and Beverage Undisputed 01/23/2026 1150813062 CMS
Neurocrine Biosciences, Inc. $2,000.00 11/20/2024 Consulting Fee Undisputed 01/23/2026 1150869276 CMS
Novo Nordisk Health Care AG $1,000.00 03/21/2024 Consulting Fee Undisputed 01/23/2026 1096553712 CMS
Novo Nordisk Health Care AG $1,000.00 05/31/2024 Consulting Fee Undisputed 01/23/2026 1096553878 CMS
Novo Nordisk Health Care AG $500.00 11/19/2024 Consulting Fee Undisputed 01/23/2026 1096553632 CMS
Novo Nordisk Health Care AG $5,375.00 11/19/2024 Consulting Fee Undisputed 01/23/2026 1096553688 CMS
Novo Nordisk Health Care AG $253.98 11/19/2024 Food and Beverage Undisputed 01/23/2026 1096553786 CMS
Novo Nordisk Health Care AG $4,400.57 11/19/2024 Travel and Lodging Undisputed 01/23/2026 1096553812 CMS
Novo Nordisk Health Care AG $342.75 11/19/2024 Travel and Lodging Undisputed 01/23/2026 1096553860 CMS
Novo Nordisk Health Care AG $551.98 11/19/2024 Travel and Lodging Undisputed 01/23/2026 1096553870 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.